Video

Managing Hypertension and Thyroid Cancer

High blood pressure is common in patients with thyroid cancer who are taking Lenvima. Here's what one expert says about managing it.

The majority of patients with iodine-refractory, differentiated thyroid cancer end up developing high blood pressure (hypertension) as a result of treatment with Lenvima (lenvatinib), according to Lori J. Wirth, M.D., associate professor of Medicine at Harvard Medical School and medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital.

If a patient develops hypertension during treatment, the medical team should not stop treatment, but instead find ways to manage the hypertension. This can include giving the patient blood pressure medications or stopping Lenvima for a period of time, but then re-administering the agent.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.
Watch oncology dietitian Kenisha Parikh prepare creamy lentil soup, a soothing, protein-packed recipe to help ease side effects during treatment.
Related Content